These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 32816895)
1. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929). Da Silva DM; Enserro DM; Mayadev JS; Skeate JG; Matsuo K; Pham HQ; Lankes HA; Moxley KM; Ghamande SA; Lin YG; Schilder RJ; Birrer MJ; Kast WM Clin Cancer Res; 2020 Nov; 26(21):5621-5630. PubMed ID: 32816895 [TBL] [Abstract][Full Text] [Related]
2. Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer. Mayadev JS; Enserro D; Lin YG; Da Silva DM; Lankes HA; Aghajanian C; Ghamande S; Moore KN; Kennedy VA; Fracasso PM; Schilder RJ JAMA Oncol; 2020 Jan; 6(1):92-99. PubMed ID: 31774464 [TBL] [Abstract][Full Text] [Related]
3. A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer. Hasan Y; Furtado L; Tergas A; Lee N; Brooks R; McCall A; Golden D; Jolly S; Fleming G; Morrow M; Kraynyak K; Sylvester A; Arif F; Levin M; Schwartz D; Boyer J; Skolnik J; Esser M; Kumar R; Bagarazzi M; Weichselbaum R; Spiotto M Int J Radiat Oncol Biol Phys; 2020 Jul; 107(3):487-498. PubMed ID: 32151670 [TBL] [Abstract][Full Text] [Related]
4. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125 [TBL] [Abstract][Full Text] [Related]
5. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial. Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284 [TBL] [Abstract][Full Text] [Related]
6. Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. Lheureux S; Butler MO; Clarke B; Cristea MC; Martin LP; Tonkin K; Fleming GF; Tinker AV; Hirte HW; Tsoref D; Mackay H; Dhani NC; Ghatage P; Weberpals J; Welch S; Pham NA; Motta V; Sotov V; Wang L; Karakasis K; Udagani S; Kamel-Reid S; Streicher HZ; Shaw P; Oza AM JAMA Oncol; 2018 Jul; 4(7):e173776. PubMed ID: 29145543 [TBL] [Abstract][Full Text] [Related]
7. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer. Aggarwal C; Cohen RB; Morrow MP; Kraynyak KA; Sylvester AJ; Knoblock DM; Bauml JM; Weinstein GS; Lin A; Boyer J; Sakata L; Tan S; Anton A; Dickerson K; Mangrolia D; Vang R; Dallas M; Oyola S; Duff S; Esser M; Kumar R; Weiner D; Csiki I; Bagarazzi ML Clin Cancer Res; 2019 Jan; 25(1):110-124. PubMed ID: 30242022 [TBL] [Abstract][Full Text] [Related]
8. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma. Zech HB; Moeckelmann N; Boettcher A; Muenscher A; Binder M; Vettorazzi E; Bokemeyer C; Schafhausen P; Betz CS; Busch CJ Future Oncol; 2020 Dec; 16(36):3035-3043. PubMed ID: 32902312 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Ascierto PA; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Maio M; Middleton MR; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Lobo M; de Pril V; Loffredo J; Larkin J; Weber J Lancet Oncol; 2020 Nov; 21(11):1465-1477. PubMed ID: 32961119 [TBL] [Abstract][Full Text] [Related]
10. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma. Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663 [TBL] [Abstract][Full Text] [Related]
11. Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy. Lauret Marie Joseph E; Kirilovsky A; Lecoester B; El Sissy C; Boullerot L; Rangan L; Marguier A; Tochet F; Dosset M; Boustani J; Ravel P; Boidot R; Spehner L; Haicheur-Adjouri N; Marliot F; Pallandre JR; Bonnefoy F; Scripcariu V; Van den Eynde M; Cornillot E; Mirjolet C; Pages F; Adotevi O J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230108 [TBL] [Abstract][Full Text] [Related]
12. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557 [TBL] [Abstract][Full Text] [Related]
13. A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Zeidan AM; Knaus HA; Robinson TM; Towlerton AMH; Warren EH; Zeidner JF; Blackford AL; Duffield AS; Rizzieri D; Frattini MG; Levy YM; Schroeder MA; Ferguson A; Sheldon KE; DeZern AE; Gojo I; Gore SD; Streicher H; Luznik L; Smith BD Clin Cancer Res; 2018 Aug; 24(15):3519-3527. PubMed ID: 29716921 [No Abstract] [Full Text] [Related]
14. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Kwek SS; Lewis J; Zhang L; Weinberg V; Greaney SK; Harzstark AL; Lin AM; Ryan CJ; Small EJ; Fong L Cancer Immunol Res; 2015 Sep; 3(9):1008-16. PubMed ID: 25968455 [TBL] [Abstract][Full Text] [Related]
15. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825 [TBL] [Abstract][Full Text] [Related]
16. Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy. Manzar GS; Alam MBE; Lynn EJ; Karpinets TV; Harris T; Lo D; Yoshida-Court K; Napravnik TC; Sammouri J; Lin D; Andring LM; Bronk J; Wu X; Sims TT; Mathew G; Schmeler KM; Eifel PJ; Jhingran A; Lin LL; Joyner MM; Zhang J; Futreal A; Klopp AH; Colbert LE Brachytherapy; 2024; 23(2):123-135. PubMed ID: 38129211 [TBL] [Abstract][Full Text] [Related]
17. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Carlino MS; Menzies AM; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Guminski AD; Kefford R; Wu H; Ibrahim N; Homet Moreno B; Long GV Clin Cancer Res; 2020 Oct; 26(19):5086-5091. PubMed ID: 32605909 [TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Youn JW; Hur SY; Woo JW; Kim YM; Lim MC; Park SY; Seo SS; No JH; Kim BG; Lee JK; Shin SJ; Kim K; Chaney MF; Choi YJ; Suh YS; Park JS; Sung YC Lancet Oncol; 2020 Dec; 21(12):1653-1660. PubMed ID: 33271094 [TBL] [Abstract][Full Text] [Related]
19. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts. de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722 [TBL] [Abstract][Full Text] [Related]
20. Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients. Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Frydecka I; Pawlak E; Szmyrka M; Kosmaczewska A Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502204 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]